Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
Table 2
TEAEs suspected by the investigator to be related to study drug, occurring in ≥2 patients, sorted by overall incidence.